New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
07:01 EDTDNDNDendreon: Immune responses enhanced when Provenge given after ADT
Dendreon Corporation announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE is given after androgen deprivation therapy in patients with biochemically-recurrent prostate cancer at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology Congress taking place from April 11-15, 2014 in Stockholm, Sweden.
News For DNDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
09:13 EDTDNDNNICE says Dendreon drug too expensive for prostate cancer use
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use